Erythromycin Panpharma
Macrolide antibiotic – Powder for solution for intravenous infusion
Erythromycin Panpharma is an intravenous macrolide antibiotic containing erythromycin (as erythromycin lactobionate). It is used to treat serious bacterial infections in adults and children when oral therapy is not feasible or sufficient, or when the patient is allergic to beta-lactam antibiotics. The infusion is administered in hospital settings under medical supervision and is available as a 1 g powder for reconstitution.
Quick Facts
Key Takeaways
- Erythromycin Panpharma is an intravenous macrolide antibiotic reserved for serious infections when oral therapy is not possible or adequate.
- It must be infused slowly over at least 60 minutes to reduce the risk of cardiac arrhythmias (QT prolongation) and local venous irritation.
- Numerous critical drug interactions exist – erythromycin must not be combined with certain antihistamines, statins, ergot alkaloids, or antiarrhythmics.
- It is contraindicated in patients with hepatic impairment, known QT prolongation, or low blood potassium or magnesium levels.
- Intravenous treatment should be switched to oral erythromycin after 2–7 days, once the acute phase is controlled.
What Is Erythromycin Panpharma and What Is It Used For?
Erythromycin Panpharma contains the active ingredient erythromycin in the form of erythromycin lactobionate, a water-soluble salt suitable for intravenous administration. It belongs to the macrolide class of antibiotics, which are among the most widely prescribed antibiotic groups worldwide. Macrolides exert their antibacterial effect by binding reversibly to the 50S subunit of susceptible bacterial ribosomes, thereby inhibiting protein synthesis and preventing bacterial growth and reproduction.
This medication is specifically formulated for intravenous use and is indicated for the treatment of serious infections caused by susceptible bacteria in both adults and children. It is particularly valuable when oral administration is not possible – for example, in patients who are unable to swallow, those with severe gastrointestinal dysfunction, or when the severity of the infection requires the high and predictable blood levels achievable only through intravenous delivery. Additionally, erythromycin serves as an important alternative for patients who are allergic or hypersensitive to beta-lactam antibiotics such as penicillins and cephalosporins.
According to the World Health Organization (WHO) Essential Medicines List, erythromycin is recognized as one of the most efficacious, safe, and cost-effective medicines needed in a health system. Its spectrum of activity covers a broad range of Gram-positive bacteria and certain Gram-negative organisms, atypical pathogens including Mycoplasma pneumoniae, Chlamydia trachomatis, and Legionella pneumophila.
Approved Indications
Erythromycin Panpharma is approved for the treatment of the following infections when caused by susceptible organisms:
- Respiratory tract infections: Community-acquired pneumonia (including atypical pneumonia caused by Mycoplasma or Legionella), pertussis (whooping cough), and other lower and upper respiratory infections
- Ear infections: Acute otitis media and other ear infections caused by susceptible bacteria
- Eye infections: Conjunctivitis and other ocular infections amenable to systemic therapy
- Skin and soft tissue infections: Cellulitis, erysipelas, wound infections, and infections involving muscles, blood vessels, tendons, and adipose tissue
- Gastrointestinal infections: Including campylobacter enteritis and other susceptible enteric infections
- Urogenital infections: Infections of the urinary tract and reproductive organs, including non-gonococcal urethritis and pelvic inflammatory disease
- Lymphogranuloma venereum: A sexually transmitted infection caused by Chlamydia trachomatis
- Diphtheria: Both as treatment and as adjunct to diphtheria antitoxin in this serious upper respiratory disease
Once the acute phase of the infection is controlled, your physician will transition from intravenous erythromycin to oral erythromycin formulations. This step-down approach is standard clinical practice and helps reduce the duration of intravenous therapy, lowering the risk of catheter-related complications.
What Should You Know Before Receiving Erythromycin Panpharma?
Contraindications
Erythromycin Panpharma must not be used in the following situations. Your healthcare provider will assess these factors before initiating treatment:
- You are allergic (hypersensitive) to erythromycin or any other macrolide antibiotic (e.g., azithromycin, clarithromycin)
- You have impaired liver function, as erythromycin is primarily eliminated through hepatic metabolism
- You or a family member has a history of cardiac rhythm disorders (ventricular arrhythmia or torsades de pointes) or a condition known as “long QT syndrome” on ECG
- You have low blood levels of potassium (hypokalemia) or magnesium (hypomagnesemia)
Erythromycin is also strictly contraindicated with the concurrent use of certain medications due to the risk of life-threatening cardiac arrhythmias or other serious adverse effects. These include astemizole, terfenadine, cisapride, pimozide, ergotamine, dihydroergotamine, lovastatin, simvastatin, atorvastatin, disopyramide, Class Ia and III antiarrhythmic agents, certain neuroleptics, tri- and tetracyclic antidepressants, fluoroquinolone antibiotics, arsenic trioxide, methadone, and budipin. The complete list of contraindicated co-medications is detailed in the drug interactions section below.
Warnings and Precautions
Speak with your physician, pharmacist, or nurse before receiving Erythromycin Panpharma if any of the following apply to you:
- Heart conditions: Inform your healthcare team if you have any existing cardiac problems, as erythromycin can prolong the QT interval on ECG, potentially leading to dangerous arrhythmias. This risk is increased with rapid infusion, which is why the drug must be administered over at least 60 minutes.
- Myasthenia gravis: Erythromycin may worsen symptoms of this neuromuscular condition, potentially causing severe respiratory difficulties. If you have myasthenia gravis, your physician will carefully weigh the benefits against the risks.
- Elderly patients: Older adults have an increased risk of developing kidney problems and erythromycin-induced hearing loss, particularly at doses of 4 g/day or higher. Dose adjustments based on renal and hepatic function are essential.
- Kidney impairment: While erythromycin is primarily eliminated through the liver, toxicity has been reported in patients with moderate to severe renal impairment. Dose reduction may be necessary.
Contact your physician immediately if your infant develops projectile vomiting (without bile) or has difficulty feeding during treatment with this medicine. There is a risk of infantile hypertrophic pyloric stenosis (IHPS), a condition that causes serious vomiting in newborns and young infants. The physician will determine the appropriate dose for your child based on their weight.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your physician or pharmacist before receiving this medicine. Erythromycin has been reported to cross the placenta and reach the unborn child. It is also excreted in breast milk. Your physician will determine whether the benefits of treatment outweigh the potential risks to the fetus or nursing infant.
According to international guidelines from the European Medicines Agency (EMA) and the British National Formulary (BNF), erythromycin is generally considered one of the safer antibiotic options during pregnancy when a macrolide is indicated. However, the intravenous formulation is reserved for situations where the clinical need clearly justifies its use. Breastfeeding women should be aware that erythromycin may cause gastrointestinal disturbances in the nursing infant.
Driving and Operating Machinery
Side effects of Erythromycin Panpharma may affect the ability to drive and operate machinery. Clinical experience indicates that erythromycin has negligible effects on concentration and reaction time under normal circumstances. However, as this medication is given intravenously in a clinical setting, patients should assess their own fitness before driving or performing tasks requiring alertness, particularly if they experience dizziness or visual disturbances.
How Does Erythromycin Panpharma Interact with Other Drugs?
Erythromycin is metabolized by and acts as a strong inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. This means it can significantly increase blood levels of many other medications that are processed by the same enzyme pathway, potentially leading to serious or life-threatening adverse effects. Always inform your healthcare provider of all medications, supplements, and herbal products you are taking.
Major Interactions (Contraindicated)
The following medications must never be used simultaneously with erythromycin due to the risk of life-threatening reactions:
| Drug | Therapeutic Class | Risk |
|---|---|---|
| Astemizole, Terfenadine | Antihistamines | QT prolongation, torsades de pointes, cardiac arrest |
| Cisapride | Gastrointestinal prokinetic | QT prolongation, ventricular arrhythmias |
| Pimozide | Antipsychotic | QT prolongation, sudden cardiac death |
| Ergotamine, Dihydroergotamine | Antimigraine (ergot alkaloids) | Ergotism: severe vasospasm, ischemia, gangrene |
| Lovastatin, Simvastatin, Atorvastatin | Statins (cholesterol-lowering) | Rhabdomyolysis, acute kidney injury |
| Disopyramide | Class Ia antiarrhythmic | QT prolongation, ventricular tachycardia |
| Class Ia & III Antiarrhythmics | Cardiac antiarrhythmics | Additive QT prolongation, cardiac arrest |
| Arsenic trioxide | Antineoplastic | QT prolongation, torsades de pointes |
| Methadone | Opioid agonist | QT prolongation, respiratory depression |
Clinically Significant Interactions (Use with Caution)
The following medications require careful monitoring, dose adjustment, or are generally not recommended in combination with erythromycin. Your physician will evaluate the risk-benefit ratio in each case:
| Drug | Category | Clinical Effect |
|---|---|---|
| Warfarin, Acenocoumarol, Rivaroxaban | Anticoagulants | Increased anticoagulant effect – bleeding risk; monitor INR closely |
| Theophylline | Bronchodilator | Increased theophylline levels – toxicity risk (nausea, seizures) |
| Digoxin | Cardiac glycoside | Increased digoxin levels – risk of toxicity (arrhythmias) |
| Carbamazepine | Antiepileptic | Increased carbamazepine levels – risk of toxicity (ataxia, nystagmus) |
| Cyclosporine, Tacrolimus | Immunosuppressants | Increased immunosuppressant levels – nephrotoxicity risk |
| Colchicine | Antigout | Increased colchicine toxicity – potentially fatal in renal/hepatic impairment |
| Midazolam, Triazolam | Benzodiazepines | Prolonged sedation; dose reduction required |
| Sildenafil | PDE5 inhibitor | Increased sildenafil levels – hypotension risk |
| Alfentanil | Opioid analgesic | Prolonged respiratory depression under anesthesia |
| Valproate | Antiepileptic / Mood stabilizer | Altered valproate levels; monitor serum concentrations |
| Omeprazole | Proton pump inhibitor | Mutual increase in blood levels |
| St. John’s Wort | Herbal supplement | May decrease erythromycin levels via CYP3A4 induction |
Erythromycin may also affect certain laboratory tests. If you are providing a urine sample, inform the laboratory that you are receiving erythromycin as it may interfere with urinary catecholamine determinations and other assays. Drugs such as rifampicin, phenytoin, and phenobarbital may reduce erythromycin levels through enzyme induction, potentially decreasing its therapeutic effectiveness.
What Is the Correct Dosage of Erythromycin Panpharma?
Erythromycin Panpharma is always administered by a physician or qualified healthcare professional in a hospital or clinical setting. It is given intravenously (into a vein) as an infusion over a minimum of 60 minutes. Rapid infusion must be avoided as it is associated with a higher incidence of QT prolongation, cardiac arrhythmias, and hypotension. For patients with risk factors for arrhythmias, a longer infusion period should be used.
Adults and Children Over 12 Years (or Weighing Over 40 kg)
Standard Dosage
The usual dose is 1 to 2 g per day, equivalent to 25 mg/kg/day, divided into 3–4 individual doses administered at regular intervals throughout the day.
Severe Infections
The dose may be increased to a maximum of 4 g per day (50 mg/kg/day) for very serious infections. The maximum daily dose must not exceed 4 g.
Children (1 Month to 12 Years or Weighing 40 kg or Less)
Pediatric Dosage
The usual daily dose is 15–20 mg/kg body weight, divided into 3–4 individual doses. This dose may be doubled depending on the indication and severity. The physician will calculate the exact dose based on the child’s weight.
Neonates (Birth to 1 Month)
Neonatal Dosage
For full-term neonates, the usual dose is 10–15 mg/kg/day divided into 3 individual doses. The physician will calculate the precise dose based on the infant’s weight and clinical status.
Elderly Patients
Adult dosing is used with caution in elderly patients. The physician will carefully determine the appropriate dose with consideration of renal and hepatic function, as elderly patients are at increased risk of developing renal complications and erythromycin-induced hearing loss, particularly at doses of 4 g/day or higher.
Patients with Kidney Impairment
For patients with mild to moderate kidney impairment (creatinine clearance above 10 mL/min), dose adjustment may not be necessary due to the low proportion of renal excretion. However, for patients with moderate to severe kidney impairment (serum creatinine of 2.0 mg/dL or higher, or creatinine clearance below 10 mL/min), the maximum daily dose is limited to 2 g, and the dose should be reduced to 50–75% of the normal dose. Erythromycin is not removed by hemodialysis or peritoneal dialysis, so supplemental doses after dialysis are not recommended.
Missed Dose
Since Erythromycin Panpharma is administered by healthcare professionals in a clinical setting, missed doses are uncommon. However, if you believe a dose has been missed, inform your doctor or nurse immediately so they can adjust the treatment schedule accordingly.
Overdose
If an overdose is suspected, contact your physician or emergency services immediately. Symptoms of overdose may include ototoxicity (ear damage), hearing loss, severe nausea, vomiting, and diarrhea. Treatment is supportive and symptomatic, as there is no specific antidote for erythromycin overdose.
It is crucial to complete the entire prescribed course of antibiotic treatment and not to discontinue the infusion early, even if you feel better. Premature discontinuation of antibiotics contributes to antimicrobial resistance, a growing global health concern identified by the WHO as one of the top 10 threats to public health. Intravenous therapy is typically continued for 2–7 days, after which your physician will switch you to oral erythromycin for an additional 2–3 days after symptoms have resolved.
What Are the Side Effects of Erythromycin Panpharma?
Like all medicines, Erythromycin Panpharma can cause side effects, although not everybody gets them. If you experience a severe allergic reaction with rash, swelling of the face and throat, or difficulty breathing, stop the medication and seek immediate medical attention. Contact your physician immediately if you develop a serious skin reaction with red, scaly rash with bumps under the skin and blisters (acute generalized exanthematous pustulosis).
The most commonly reported side effects are gastrointestinal in nature, including loss of appetite, nausea, vomiting, abdominal pain, stomach discomfort, flatulence, cramps, soft stools, and diarrhea. These effects are related to erythromycin’s motilin receptor agonist activity, which stimulates gastrointestinal motility.
Common Side Effects
May affect up to 1 in 10 people
- Nausea, vomiting, abdominal pain, and diarrhea
- Loss of appetite, flatulence, stomach cramps
- Pain or irritation at the injection site
Uncommon Side Effects
May affect up to 1 in 100 people
- Oral thrush (candida infection) with white coating in the mouth
- Vaginal inflammation, genital itching in women
- Allergic reactions, widespread rash (urticaria), skin itching
- Skin redness with increased blood flow (flushing)
- Abnormal liver and gallbladder function values
- Swelling and redness along a vein (phlebitis), extremely tender to touch
Rare Side Effects
May affect up to 1 in 1,000 people
- Angioedema (swelling of face, lips, tongue, or throat), anaphylaxis
- Pancreatitis (severe abdominal pain radiating to the back)
- Cholestatic jaundice (itching with yellowing of skin, pale stools, dark urine)
- Joint swelling, fever
- Pseudomembranous colitis (severe inflammation of the colon with bloody diarrhea)
Very Rare Side Effects
May affect up to 1 in 10,000 people
- Worsening of myasthenia gravis
- Tinnitus (ringing in the ears) and mostly reversible hearing loss
- Abnormal liver function, abnormal kidney function
- Stevens-Johnson syndrome, erythema multiforme
- Toxic epidermal necrolysis (severe skin peeling)
Frequency Not Known
Cannot be estimated from available data
- Cardiac arrhythmias including palpitations, tachycardia, life-threatening torsades de pointes, QT prolongation, or cardiac arrest
- Chest pain, chest discomfort, dyspnea (difficulty breathing)
- Hypotension (low blood pressure)
- Visual disturbances including double vision and blurred vision
- Psychiatric disturbances (mood swings, impaired judgment), confusion, hallucinations
- Dizziness, fatigue, vertigo, headache
- Seizures, convulsions
- Blood disorders affecting blood cells (typically identified through blood tests)
Projectile vomiting (without bile) or difficulty feeding and weight loss may occur in neonates and infants (infantile hypertrophic pyloric stenosis). Parents and caregivers should be alert to these symptoms and contact the treating physician immediately if they occur.
The risk of cardiac side effects is increased with rapid IV administration, higher doses, and in patients with pre-existing cardiac conditions, electrolyte abnormalities, or concomitant use of other QT-prolonging medications. The risk of hepatotoxicity increases with prolonged treatment courses. If you notice any side effects not listed here, or if any side effect becomes severe, inform your healthcare provider promptly.
How Should You Store Erythromycin Panpharma?
Proper storage of Erythromycin Panpharma is essential to maintain the stability and efficacy of the medication. As this is a hospital-administered product, storage is typically managed by pharmacy and nursing staff; however, the following guidelines apply:
- Unopened vials: Store at room temperature, protected from light, and keep out of sight and reach of children. Do not use after the expiry date printed on the vial and carton.
- After reconstitution (stock solution): Chemical and physical stability has been demonstrated for 24 hours when stored in a refrigerator at 2–8°C. From a microbiological standpoint, the product should be used immediately.
- After dilution (infusion solution): Chemical and physical stability has been demonstrated for 24 hours when stored in a refrigerator at 2–8°C. The diluted solution should ideally be used immediately after preparation.
- Do not freeze the reconstituted or diluted solution.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures help protect the environment.
The reconstituted stock solution (50 mg/mL) is prepared using water for injection only – saline (0.9% sodium chloride) must not be used for the initial reconstitution step as it may cause precipitation. For the subsequent dilution step, either 0.9% sodium chloride or 5% glucose solution may be used. Each vial is for single use only.
What Does Erythromycin Panpharma Contain?
Erythromycin Panpharma has a notably simple formulation:
- Active substance: Erythromycin (as erythromycin lactobionate) – 1 g per vial
- Excipients: None. This medicine contains no other ingredients.
The product is supplied as a white to slightly yellow hygroscopic powder for solution for infusion in a glass vial. After reconstitution with water for injection, the resulting solution is clear and colorless. Erythromycin Panpharma is available in packs of 1, 10, or 25 glass vials. Not all pack sizes may be marketed in every country.
Preparation and Administration (For Healthcare Professionals)
Preparation requires a two-step process:
- Reconstitution: Add 20 mL of water for injection to the vial containing 1 g erythromycin to prepare a stock solution of 50 mg/mL. Do not use sodium chloride solution for this step. Shake vigorously until completely dissolved – this may take several minutes.
- Dilution: For intermittent infusion, add the 20 mL stock solution to 200–500 mL of 0.9% sodium chloride or 5% glucose solution (final concentration 2–5 mg/mL). For continuous infusion, dilute in 500–1000 mL (final concentration 1–2 mg/mL).
The concentration must not exceed 5 mg/mL, and a concentration of 1 mg/mL is recommended. At least 200 mL of diluent should be used for intermittent infusion to minimize venous irritation. Erythromycin lactobionate is incompatible with beta-lactam antibiotics, aminoglycosides, tetracyclines, chloramphenicol, colistin, aminophylline, barbiturates, heparin, phenothiazines, and vitamins B6, B12, and C. Intra-arterial injection is strictly contraindicated, as is intramuscular injection and intravenous bolus injection.
This medicine is approved in several EU member states including Denmark, Finland, Germany, Norway, Spain, Sweden, and the United Kingdom under the name Erythromycin Panpharma (with slight naming variations by country).
Frequently Asked Questions
Erythromycin Panpharma is an intravenous macrolide antibiotic used to treat serious bacterial infections when oral treatment is not possible or sufficient. It is indicated for respiratory tract infections (including pneumonia and whooping cough), ear and eye infections, skin and soft tissue infections, gastrointestinal infections, urogenital infections, lymphogranuloma venereum, and diphtheria. It is also used as an alternative in patients allergic to beta-lactam antibiotics like penicillin.
The intravenous form of erythromycin is reserved for situations where oral administration is not feasible (e.g., the patient cannot swallow or has severe gastrointestinal problems) or when the severity of the infection demands the high and predictable blood levels that only intravenous delivery can achieve. Once the acute infection is controlled (typically after 2–7 days), the physician will switch to oral erythromycin to complete the course of treatment.
The most serious side effects include cardiac arrhythmias (QT prolongation, torsades de pointes, and cardiac arrest), which are more likely with rapid infusion or in patients taking other QT-prolonging drugs. Severe allergic reactions (anaphylaxis), hepatotoxicity (cholestatic jaundice), pseudomembranous colitis, and life-threatening skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) are rare but serious. These risks are why erythromycin IV must be administered under medical supervision in a clinical setting.
Erythromycin crosses the placenta and is excreted in breast milk. According to the EMA and BNF guidelines, erythromycin is generally considered one of the safer macrolide options during pregnancy when an antibiotic of this class is needed. However, the intravenous formulation should only be used when the clinical benefit clearly outweighs the potential risks. Your physician will make this determination on a case-by-case basis. Breastfeeding mothers should be aware that erythromycin may cause gastrointestinal effects in the nursing infant.
Each infusion must be administered over at least 60 minutes. Rapid infusion is associated with a significantly higher risk of QT prolongation, cardiac arrhythmias, hypotension, and local venous irritation. For patients with risk factors for arrhythmias or a history of cardiac problems, a longer infusion period should be used. At least 200 mL of diluent should be used for intermittent infusions to further minimize the risk of venous irritation at the infusion site.
During the initial reconstitution step, only water for injection should be used. Sodium chloride solutions or other solutions containing inorganic salts cause erythromycin lactobionate to precipitate out of solution, rendering the preparation unusable. However, once the stock solution has been prepared with water for injection, it can then be further diluted with 0.9% sodium chloride or 5% glucose for infusion. This two-step process is essential for proper preparation.
References
This article is based on the following peer-reviewed sources and authoritative guidelines:
- European Medicines Agency (EMA). Erythromycin – Summary of Product Characteristics. European Public Assessment Reports. Available at: www.ema.europa.eu
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- British National Formulary (BNF). Erythromycin – drug monograph. NICE Evidence Services. Available at: bnf.nice.org.uk
- Infectious Diseases Society of America (IDSA). Practice Guidelines for the Management of Community-Acquired Pneumonia. Clinical Infectious Diseases. 2019;68(6):e1–e48. doi:10.1093/cid/ciy866
- Patel SJ, Saiman L. Antibiotic resistance in NICU pathogens: mechanisms, clinical impact, and prevention. Clinics in Perinatology. 2010;37(3):547–563. doi:10.1016/j.clp.2010.06.004
- Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics. 1992;23(2):106–131. doi:10.2165/00003088-199223020-00004
- Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. New England Journal of Medicine. 2012;366(20):1881–1890. doi:10.1056/NEJMoa1003833
- WHO Antimicrobial Resistance Global Report on Surveillance. World Health Organization, 2023.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in infectious disease, clinical pharmacology, and antimicrobial therapy.
iMedic Medical Editorial Team
Specialists in Infectious Disease & Clinical Pharmacology
iMedic Medical Review Board
Independent review following WHO, EMA & BNF guidelines
All content follows the GRADE evidence framework and is free from commercial funding or pharmaceutical industry influence. For questions about our editorial standards, please visit our Editorial Standards page.